阿哌沙班(Apixaban) - 药物靶点：factor Xa_在研适应症：复发性深静脉血栓形成，血栓形成，缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Apixaban (JAN/USAN/INN)、T20j、BMS-562247

+ [14]

靶点

factor Xa

作用方式

抑制剂

作用机制

factor Xa抑制剂(激活型凝血因子X抑制剂)

治疗领域

神经系统疾病心血管疾病呼吸系统疾病+ [1]

在研适应症

复发性深静脉血栓形成血栓形成缺血性卒中+ [11]

非在研适应症

急性冠状动脉综合征急性缺血性卒中急性淋巴细胞白血病+ [27]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.Accord Healthcare SLUBristol-Myers Squibb KK

+ [6]

非在研机构

Pfizer Inc.

Celgene Corp.Wyeth AB

权益机构

Pfizer Inc.

Bristol Myers Squibb Co.

最高研发阶段批准上市

首次获批日期

欧盟 (2011-05-18),

心房颤动栓塞肺栓塞+ [3]

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C25H25N5O4

InChIKeyQNZCBYKSOIHPEH-UHFFFAOYSA-N

CAS号503612-47-3

关联

426

项与阿哌沙班相关的临床试验

NCT07160686

/ Not yet recruiting临床3期

A Phase III, Multicentre, Double Blind, Placebo-Controlled, Randomised Clinical Trial of Apixaban THROMBOprophylaxiS TO Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming.
The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer.
Participants will receive the following treatment:
• Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will be taken in addition to any treatment that they are receiving to treat their lung cancer.
Participants will need to:
* Sign a consent form to enter the trial.
* Take the trial treatment as directed by the research team
* Complete a participant diary to record when they took the trial treatment
* Complete the Quality of Life and Health resource use questionnaires.
* Female participants of childbearing potential must use adequate contraception during the trial and for at least 2 days after trial treatment has finished.

开始日期2026-03-02

申办/合作机构

University of Birmingham

NCT07189897

/ Recruiting临床4期IIT

An Open-label Pilot Study to Evaluate Medication Satisfaction With Apixaban Versus Enoxaparin for Thrombosis Prevention After Head and Neck Cancer Surgery

The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines.
The main questions it aims to answer are:
Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine?
Researchers will compare 2 groups:
One group will take apixaban (a pill taken twice a day) for 10 days after surgery.
The other group will take enoxaparin (a shot given once a day) for 10 days after surgery.
Participants will:
Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks
How long will participation last? About 4 months from surgery through the last follow-up visit.

开始日期2025-10-01

申办/合作机构

SUNY Upstate Medical University

[+1]

NCT06474182

/ RecruitingN/AIIT

Comparison of the Effects of Prophylactic Administration of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma and Patients Undergoing a Surgery for Total Knee Replacement

Patients with multiple myeloma (MM) are at high risk of venous thromboembolism (VTE) and these patients require adequate thromboprophylaxis. Following the publication of the AVERT clinical study, Apixaban is strongly recommended as a prophylactic treatment option for patients with cancer, based on high quality of evidence and a favorable efficacy/safety profile. A multicenter and ancillary study - APIXABOR - that measured the plasmatic concentration of Apixaban in patients with MM and treated with preventive dose has been conducted. The peak drug concentration was superior in MM plasma, as compared to non-myeloma patients under prophylaxis. Therefore, the present study evaluated whether differences in pharmacokinetics have an impact on pharmacodynamics (i.e. decrease in coagulability in MM patients as compared to non-MM patients undergoing a surgery for total knee replacement who also have VTE prophylaxis). In fine, this study may inform to better manage thromboprophylaxis in MM patients.

开始日期2025-09-15

申办/合作机构

Centre Hospitalier Universitaire de Saint-Etienne

100 项与阿哌沙班相关的临床结果

登录后查看更多信息

100 项与阿哌沙班相关的转化医学

登录后查看更多信息

100 项与阿哌沙班相关的专利（医药）

登录后查看更多信息

6,694

项与阿哌沙班相关的文献（医药）

2026-02-01·BIOMATERIALS

Self-adaptive covalent coating for vascular stents: Coordinated coagulation-inflammation regulation to support re-endothelialization for atherosclerosis control

Article

作者: Xiao, Yun ; Zhang, Wenbin ; Wang, Yanan ; Chen, Zhezhe ; Luo, Rifang ; Ma, Boxuan ; Zhu, Qiongjun ; Wang, Yao ; Fu, Guosheng ; Wang, Yunbing ; Wang, Xiaoyu

Therapeutic-coated vascular stents are one of the key directions in the clinical treatment of atherosclerosis. However, vascular injury and implant stimulation trigger a feedback loop between coagulation and inflammation, impairing endothelial cell (EC) function, which is critical for long-term success in atherosclerotic vessels. Here, we designed a self-adaptive covalent coating stent that integrates thrombin-responsive release of apixaban as a coagulation modulator and an antioxidant polyphenol as an anti-inflammatory. This pathologic microenvironment-responsive coating regulates coagulation-inflammation loop post-implantation. The nanogels within the coating dynamically response to thrombin, the upstream initiator of coagulation-inflammation, to release apixaban in high thrombotic risk conditions while retaining it in low-risk states. Epigallocatechin gallate (EGCG), functioning as a cross-linker and the ROS scavagener, detaches in response to oxidative stress. As such, the coating enables blockade of coagulation-inflammation loop, synergistically protects ECs from inflammatory damage, promotes endothelial regeneration, and inhibits endothelial-to-mesenchymal transition (EndMT), efficiently modulating the inflammatory microenvironment via localized and coordinated regulation of coagulation-inflammation loop. Furthermore, the implantation in an atherosclerotic rabbit model demonstrated that the coating inhibits plaque deterioration linked to inflammation and endothelial damage. This dual-responsive strategy offers a promising avenue for therapeutic stents by mitigating the coagulation-inflammation loop and supporting endothelial repair in atherosclerotic vessels.

2026-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Harmonizing drug analysis and sustainability: Spectroscopic quantification of antiplatelet-anticoagulant regimens

Article

作者: Elama, Heba Samir ; El Abass, Samah Abo ; Altamimi, Abdulmalik S A ; Elmansi, Heba ; Abdallah, Nora A ; Alossaimi, Manal A

One of the most commonly prescribed medications are antithrombotic agents which consisting of antiplatelet and anticoagulant medications. Currently, millions of patients rely on them to avoid blood-clot-related issues across various cardiovascular diseases. The combined administration of apixaban, aspirin and clopidogrel is an example of this therapy which can be used for the risk reduction in cardiovascular death. The importance of such medications encourages us to investigate novel analytical assay methods for determination of such drugs in dosage forms as well as in human plasma. Spectroscopic technique was the best choice to design new analytical methods due to its applicability and simplicity. Three spectroscopic methods were introduced for concurrent determination of apixaban, aspirin and clopidogrel. The designed methods were; A direct measurement for determination of apixaban without interference from the other two drugs (method I), Ratio spectra (method II) and first derivative ratio spectra (method III). The first method enables us to determine apixaban through direct measurement of its absorption spectrum at 310 nm with no reading from aspirin or clopidogrel. Ratio spectra method (method II) was performed at ΔP = 223.6-245.2 nm for aspirin, ΔP = 293.2-307.0 nm for apixaban and ΔP = 251.0-260.0 nm for clopidogrel. The third first derivative ratio spectra method was based on measuring apixaban at 255 nm, aspirin at 242 nm and clopidogrel at 260 nm using the other two analytes as a double divisor. The linearity of the designed methods was 0.5-18 μg/mL for apixaban by the three methods while were 2.0-28 μg/mL for both aspirin and clopidogrel by method II & III. These developed approaches were effectively applied for estimation of the three studied drugs in their raw materials, synthetic mixtures and dosage forms simultaneously. The co-administration of these treatments enables us to extend the application for determination of them in spiked human plasma without complicated procedures. The applied methods were validated following the ICH Q2(R1) guidelines. The greenness of the designed methods was evaluated using six different tools including; Analytical Eco-scale, GAPI, AGREE metrics, NEMI, whiteness and blueness assessment.

2026-01-01·INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants

Article

作者: Sakamoto, Daisuke ; Nagashima, Kouichi ; Okumura, Yasuo ; Watanabe, Ryuta ; Sotomi, Yohei ; Matsuoka, Yuki ; Sunaga, Akihiro ; Higuchi, Yoshiharu ; Nakatani, Daisaku ; Kanda, Takashi ; Kitamura, Tetsuhisa ; Okada, Katsuki ; Minamiguchi, Hitoshi ; Sakata, Yasushi

BACKGROUND:

Renal function influences the pharmacokinetics of oral anticoagulants in atrial fibrillation (AF), potentially affecting both efficacy and bleeding risk. However, its differential impact across specific agents remains unclear. In this study, we aimed to evaluate the association between renal function and ischemic and bleeding risks in patients with AF, with analyses stratified by anticoagulant type.

METHODS:

We analyzed 7239 patients with non-valvular AF from the DIRECT-Extend registry, a pooled dataset of three large-scale registries. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault formula and categorized into ≥50, 30 to <50, and 15 to <30 mL/min. The primary ischemic endpoint was stroke or systemic embolism, and the primary bleeding endpoint was major bleeding. Cox proportional hazard models and restricted cubic spline analyses assessed associations between CrCl and outcomes, with subgroup analyses by anticoagulant type.

RESULTS:

Lower CrCl was associated with older age, female sex, and greater comorbidity burden. Impaired renal function was significantly associated with higher ischemic and bleeding risks. Spline analysis demonstrated a continuous increase in both risks with declining CrCl, with a nonlinear relationship for bleeding. Subgroup analyses revealed significant associations between reduced CrCl and ischemic risk in patients on dabigatran, rivaroxaban, edoxaban, and warfarin. Increased bleeding risk was evident for edoxaban and warfarin at lower CrCl levels. No significant association was observed between CrCl and either endpoint in patients receiving apixaban.

CONCLUSION:

In this large real-world cohort, declining renal function was associated with increased ischemic and bleeding risks, highlighting the importance of renal function-based risk assessment in the management of anticoagulation therapy.

852

项与阿哌沙班相关的新闻（医药）

2025-10-01

·PRNewswire

TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world's first Apixaban Oral Dissolving Film (ODF). This submission marks a significant regulatory milestone in TAHO Pharma's mission to bring innovative and accessible therapies to patients worldwide. TAH3311 is an innovative formulation designed to improve the delivery of apixaban, a widely used anticoagulant. Stroke affects more than 15 million people worldwide each year according to NIH, and over 50% of stroke survivors experience dysphagia, which places them at heightened risk for pneumonia, malnutrition, dehydration, and a reduced quality of life. Developed on TAHO's proprietary Transepithelial Delivery System (TDS) platform, TAH3311 is formulated as an easy-to-use oral dissolving film (ODF). This patient-friendly format is particularly beneficial for stroke survivors, elderly patients, and others with swallowing difficulties, offering both greater convenience and improved treatment adherence. By eliminating the need for swallowing solid dosage forms, TAH3311 helps reduce the risk of choking and aspiration pneumonia, addressing a critical unmet need in anticoagulant therapy. "The NDA submission for TAH3311 reflects our unwavering commitment to addressing unmet patient needs through cutting-edge science," said Dr. Lee, CEO of TAHO Pharmaceuticals. "We are proud to offer a patient-centered solution that has the potential to redefine the standard of care in anticoagulant therapy." This NDA submission is a pivotal step toward U.S. market entry, supporting TAHO Pharma's broader vision to improve patient experiences and therapeutic outcomes through novel drug delivery platforms. TAHO is actively seeking global partnership opportunities to accelerate the product's time to market. About Apixaban Apixaban (co-developed by BMS and Pfizer under the brand name Eliquis®) is a direct factor Xa inhibitor and has been approved for clinical use in several thromboembolic disorders, including stroke prevention in non-valvular atrial fibrillation, thromboprophylaxis after hip/knee replacement, and the treatment and prevention of deep vein thrombosis or pulmonary embolism. With notable safety advantages, it is the leading novel oral anticoagulant (NOAC). About TAHO Pharmaceuticals Ltd. Founded in 2010, TAHO Pharma is a global small-to-medium enterprise (SME) specializing in innovative oral and transdermal drug delivery systems. Through its proprietary Transepithelial Delivery System (TDS) platform, TAHO enables efficient transdermal and transmucosal delivery of small-molecule drugs. The TDS platform provides significant advantages over conventional delivery routes, including tailored release profiles (from rapid onset to sustained delivery), reduced gastrointestinal side effects, enhanced bioavailability, and simplified administration for patients with compliance challenges. With TAHO's scientifically differentiated technology and clinically meaningful solutions, TAHO is dedicated to advancing patient care and improving quality of life worldwide. Media Contact: TAHO Pharmaceuticals +886-2-2659-8515 [email protected] SOURCE Taho Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

申请上市

2025-09-29

·药时代

70%大跳水！又一MNC药品降价，背后竟是特朗普政策倒计时

中国创新药走进“三时代”，三抗、三抗TCE、三抗ADC等新的形式陆续涌现。目前欧美药企、VC公司积极寻找三抗产品，尤其是三抗TCE（比如：CD38xCD3xBCMA、CD38xCD3xCD28、CD38xCD3xGPRC5D）。请感兴趣的公司立即联系药时代BD团队（BD@drugtimes.cn）！正文共：1400字预计阅读时间：4分钟 2025年8月1日，特朗普在其社交平台Truth Social上公布了致17家跨国药企的公开信，要求这些头部药企在60天内执行「最惠国」政策。在截止日期迫在眉睫之际，继礼来、BMS后，又一家MNC作出回应。来源：阿斯利康官网近日，阿斯利康宣布，从2025年10月1日起，通过其全新推出的AstraZeneca Direct上线平台，持有Airsupra（沙丁胺醇/布地奈德）或 Farxiga（达格列净）处方的符合条件的患者能够直接购买这些药品，且现金价格最高可优惠 70%。以Farxiga（达格列净）为例，30天疗程的价格将从此前600美元降至181.59美元。这一价格已接近美国联邦医疗保险（Medicare）和医疗补助（Medicaid）计划将于2026年起为参保患者设定的178美元支付标准。线上平台的优惠价格预计将能吸引广泛的自费患者群体。达格列净是阿斯利康目前最畅销的产品之一，2024年全球销售额达77亿美元，占公司总收入的约14%。然而，其在美国市场的定价长期备受争议：目前原研药单价约为6美元/片，而在中国经国家医保谈判后，同一药品的支付价格仅为4.36元人民币/片（约合0.6美元），美国药价约为中国医保药价的10倍。这一价差主要源于原研企业的专利壁垒（化合物、晶型及适应症专利保护至2028年）。 AstraZeneca Direct平台的推出，表面上看是响应特朗普的最惠国政策。而从长远来看，这能为符合条件的患者显著简化用药获取流程，以透明的现金价格获取处方药物，并享受直接送货上门服务。平台初期将重点支持患有哮喘、糖尿病、心力衰竭和慢性肾病等慢性疾病的患者，以及寻求流感防护的人群。值得一提的是，患者还可以通过该线上平台订购 FLUMIST®（流感减毒活疫苗，鼻内给药）并享受送货上门服务。此次推出的线上平台不仅是服务模式的创新延伸，也被视为制药行业在日益增长的政策压力下，推动药价透明化与患者可负担性的重要实践。阿斯利康美国区总裁 Joris Silon 表示："我们始终致力于改善医疗服务的可及性、可负担性，并推动医疗创新。我们很高兴推出AstraZeneca Direct，这将为患者提供透明的现金价格和便捷的送货上门服务。该计划是对我们现有患者支持服务的补充，是向患者提供所需药物的重要一步，无论何时何地，以他们需要的方式。" 就在阿斯利康官宣其AstraZeneca Direct平台前夕， BMS于2025年9月24日率先宣布，将对旗下两款核心产品：抗凝药Eliquis（阿哌沙班）和银屑病新药Sotyktu（氘可来昔替尼）实施大幅价格下调。 Eliquis降价的消息，早在本月初就已宣布。9月8日，BMS与辉瑞联合推出“Eliquis 360 Support”直销计划，为购买Eliquis的自费患者打折40%。而Sotyktu的大幅降价则是通过BMS全新推出的患者直连平台 “BMS Patient Connect”实现，该平台将于2026年1月正式启用。符合条件的自费患者每月仅需支付950美元，Sotyktu价格降幅高达86%（原价约6828美元）。与阿斯利康推出AstraZeneca Direct如出一辙，BMS在BMS Patient Connect线上平台中推出降价药品，不仅是响应特朗普的「最惠国政策」，更是一次主动的市场战略布局。借助自建的患者直销平台，制药企业得以绕过传统供应链中的保险壁垒与复杂的分销网络，直接向自费患者提供接近联邦医保价格的创新药物。这一举措显著提升了高值药品的可及性，尤其惠及那些暂时缺乏保险覆盖的患者群体。更重要的是，该模式正在重塑药品市场的准入逻辑。通过掌控定价与销售渠道，药企在提升服务效率的同时，也在一定程度上削弱了医生处方习惯、渠道资源倾斜对药品渗透率的主导作用。展望未来，随着药价透明化成为不可逆转的趋势，叠加「最惠国政策」影响，更多MNC或将跟进“数字化平台 + 主动降价”的组合策略。这不仅是一种应对监管压力的权宜之计，更是企业从“以渠道为中心”向“以患者为中心”转型的关键路径。参考资料： 1.https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-launches-direct-to-consumer-platform-to-expand-access-to-medications-for-US-patients-including-those-living-with-chronic-conditions.html 2.这款银屑病药物，降价超80%！（公众号：药时代） 3.特朗普「点名」17家药企，降低药价，补贴美国！（内附信件原文）（公众号：药时代） 4.其他公开资料图片来源：即梦AI Biogen终止AAV基因治疗业务！AAV已成时代眼泪？ 2025-09-28 这款银屑病药物，降价超80%！ 2025-09-28 上市企业寻找收购标的，优先考虑创新药公司 2025-09-28 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩！

抗体药物偶联物疫苗

2025-09-26

·医药健闻

默克集团确定新任CEO；罗氏目标成为全球前三大减肥药生产商；莫德纳将向英国研发投资超过10亿英镑 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态默克集团（Merck KGaA）正式宣布，现任电子业务CEO Kai Beckmann将自2026年5月1日起接任Belén Garijo，担任集团执行董事会主席兼首席执行官。Garijo将按计划在2026年4月底完成任期，以确保管理层平稳过渡。Beckmann即日起将担任副CEO，并继续负责电子业务直至继任者确定。Belén Garijo在默克任职15年，其中6年担任医疗健康业务CEO，自2021年起担任集团执行董事会主席兼CEO。在中国市场，Garijo大力拓展了默克医疗健康业务的布局。卸任后，她将继续活跃于医疗健康领域，专注于满足患者需求。美国生物技术公司莫德纳新尖端研究中心在英国牛津郡启用。作为与英国政府十年战略合作的组成部分，莫德纳将向英国研发投资超过10亿英镑：以发现新疗法、创造就业机会，并增强疫情应对能力。美国医疗用品制造商麦朗(Medline)正考虑最快于10月底提交首次公开募股(IPO)申请，若顺利推进，此次上市有望成为今年美国规模最大的IPO交易。麦朗此次IPO拟募资约50亿美元，其背后投资方包括黑石集团、凯雷集团与Hellman & Friedman。麦朗估值或最高达500亿美元。Medline主要生产医院与医疗机构使用的医疗用品，涵盖手套、手术衣、检查床等品类，目前在全球拥有超过4.3万名员工，2024年净销售额约为255亿美元。 Harbor Health从VillageMD收购了32家诊所，继续扩大其在德克萨斯州的临床足迹。该交易将公司的业务范围扩大到三个新市场：圣安东尼奥、埃尔帕索和达拉斯。Harbor Health还扩大了其在总部奥斯汀的既定临床足迹。此次收购使Harbor Health的临床业务几乎翻了两番，诊所总数从11家增加到43家，并增加80多名临床医生。合同开发与制造组织（CDMO）Catalent Pharma Solutions宣布其位于美国佛罗里达州坦帕市的新全球总部正式启用。年初，Catalent宣布将从美国新泽西州萨默塞特的前总部迁出，在新泽西州布里奇沃特开设公司办公室，并在坦帕建立新的公司总部。此次进驻坦帕体现了公司在佛罗里达州的战略扩张。新总部毗邻位于圣彼得堡的50万平方英尺生产基地，该生产基地在当地深耕多年，拥有逾630名员工，是公司在北美地区主要的软胶囊研发与生产基地。西门子医疗宣布参与CRISPR诊断specialist VedaBio的2500万美元A轮扩展融资并签署战略合作协议。这是VedaBio短期内完成的第二轮重磅融资。在此之前，该公司已在初始A轮融资中斩获4000万美元，由OMX Ventures独家领投。本次A轮扩展融资西门子医疗作为战略投资方强势入局，将融资总规模进一步扩大至6500万美元。欧林生物公告，正在筹划发行境外股份(H股)并申请在香港联合交易所有限公司挂牌上市事宜。成立之初，公司便确立了“仿创结合、双轮驱动”的发展战略：一方面通过仿制药快速进入市场积累资本，另一方面聚焦创新疫苗研发以构筑核心竞争力。5月份，该公司重组金黄色葡萄球菌疫苗取得重要进展。产业动态瑞士制药商罗氏(Roche)的一种实验性减肥药已进入后期试验阶段，该公司表示，其目标是成为全球前三大减肥药生产商，与诺和诺德和礼来形成竞争。罗氏目前还没有任何批准上市的减肥药，该公司的目标是到2030年推出全套治疗方案。罗氏本周早些时候表示，其CT-388减肥注射剂已进入三期试验，这是公司寻求监管部门批准前的最后阶段。这标志着罗氏在肥胖症及相关疾病治疗方面的最新进展。礼来已停止一项旨在防止肥胖患者肌肉过度流失的实验性药物研究，理由是出于战略性商业考量。此外，礼来还计划在印度推出其实验性减肥药orforpligron。该公司认为，在这个全球人口最多的国家，此类产品具有发展空间。礼来公司宣布，欧盟委员会已批准其阿尔茨海默病治疗药物Kisunla（donanemab）上市，该药物用于治疗早期症状性阿尔茨海默病的特定情况。百时美施贵宝将以优惠价格向符合条件的患者提供其中重度斑块状银屑病药物Sotyktu，价格比其当前标价低80%。此前该公司亦宣布针对抗凝血药Eliquis的折扣计划，以回应特朗普政府要求制药行业降低药品价格。药明生物推出定点整合CHO细胞株开发平台TrueSite TI，凭借对抗体及复杂药物分子细胞株质量的显著优化、工艺放大的卓越稳定性，以及研发周期的大幅缩短，为创新生物药研发提供更具竞争优势的全新解决方案。定点整合是一种以精准化为核心的细胞工程技术，能够将目的蛋白导入宿主细胞中预先确定且经过严格验证的位点。TrueSite TI是药明生物WuXia第四代细胞株开发平台。美国总统特朗普宣布从10月1日起对一批进口商品加征关税。其中，进入该国的“任何品牌或专利药品”将被征收100%的关税，但不适用于在美国当地建造制药厂的公司，涉及已动工或正在建设项目的公司将被豁免。联系美通社 +86-10-5953 9500 info@prnasia.com

并购IPO高管变更

100 项与阿哌沙班相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03213	阿哌沙班	B01AF02	DB06605

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性深静脉血栓形成	欧盟	Accord Healthcare SLU	2020-07-23
复发性深静脉血栓形成	冰岛	Accord Healthcare SLU	2020-07-23
复发性深静脉血栓形成	列支敦士登	Accord Healthcare SLU	2020-07-23
复发性深静脉血栓形成	挪威	Accord Healthcare SLU	2020-07-23
血栓形成	中国	Bristol-Myers Squibb/Pfizer EEIG	2013-01-22
缺血性卒中	日本	Bristol-Myers Squibb KK	2012-12-25
全身性栓塞	澳大利亚	Bristol Myers Squibb Co.	2011-07-21
心房颤动	欧盟	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
心房颤动	冰岛	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
心房颤动	列支敦士登	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
心房颤动	挪威	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
栓塞	欧盟	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
栓塞	冰岛	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
栓塞	列支敦士登	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
栓塞	挪威	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
肺栓塞	欧盟	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
肺栓塞	冰岛	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
肺栓塞	列支敦士登	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
肺栓塞	挪威	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18
脑卒中	欧盟	Bristol-Myers Squibb/Pfizer EEIG	2011-05-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肢体威胁性缺血	临床3期	巴西	Wyeth AB	2020-01-09
认知功能障碍	临床3期	美国	Bristol Myers Squibb Co.	2018-12-19
认知功能障碍	临床3期	美国	Pfizer Inc.	2018-12-19
基底细胞癌	临床3期	奥地利	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	比利时	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	加拿大	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	法国	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	希腊	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	意大利	Bristol Myers Squibb Co.	2018-10-11
基底细胞癌	临床3期	荷兰	Bristol Myers Squibb Co.	2018-10-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04168203 (HI-PRO, CTgov)	临床4期	肺栓塞 \| 静脉血栓形成 \| 静脉血栓栓塞	600	Apixaban 2.5 MG (Extended Duration Thromboprophylaxis)	範鏇壓蓋淵膚選醖積鏇 = 鹽鹽獵齋憲鏇築鑰襯窪範簾窪顧鏇艱鑰觸蓋鬱 (窪顧繭膚願積鹹顧夢膚, 範構構憲鹽獵鏇淵衊選 ~ 膚廠製艱積鏇鑰蓋糧網) 更多	-	2025-09-30
				Placebo oral tablet (Control)	範鏇壓蓋淵膚選醖積鏇 = 膚壓窪積衊範窪範鑰窪範簾窪顧鏇艱鑰觸蓋鬱 (窪顧繭膚願積鹹顧夢膚, 簾窪選簾製選簾簾餘獵 ~ 襯選獵廠遞窪窪選願鏇) 更多
NCT03192215 (ARCADIA-Cognition, Pubmed \| J Am Heart Assoc)	临床3期	隐源性缺血性脑卒中 \| 心脏病 atrial cardiopathy	249	Apixaban	選構廠壓膚鑰積鏇簾艱(醖憲鹽繭鏇鏇願選廠築) = 壓壓衊築窪壓顧獵鏇蓋膚醖膚廠餘廠憲鬱繭繭 (顧窪繭積選艱觸遞願壓, 0.041 ~ 0.174)	不佳	2025-09-16
				Aspirin	選構廠壓膚鑰積鏇簾艱(醖憲鹽繭鏇鏇願選廠築) = 選獵窪鏇鬱鑰獵夢醖簾膚醖膚廠餘廠憲鬱繭繭 (顧窪繭積選艱觸遞願壓, 0.017 ~ 0.149)
NCT05438888 (Pubmed \| Cardiol Ther)	N/A	心房颤动	-	Apixaban	蓋範鏇遞夢鑰壓餘簾廠(繭簾蓋夢構簾憲構艱襯) = 鹹築衊鏇齋鑰遞醖醖壓構艱鬱憲網築簾製築願 (製鏇廠淵鬱顧齋壓獵衊 ) 更多	积极	2025-07-08
				Warfarin	蓋範鏇遞夢鑰壓餘簾廠(繭簾蓋夢構簾憲構艱襯) = 憲淵膚壓襯構鏇醖鬱鏇構艱鬱憲網築簾製築願 (製鏇廠淵鬱顧齋壓獵衊 ) 更多
NCT04504318 (CTgov)	临床1/2期	静脉血栓栓塞	82	Apixaban 2.5 MG Oral Tablet (Apixaban)	壓齋構醖糧膚壓衊憲遞 = 夢獵襯鬱衊構鏇願襯廠夢鬱糧餘構繭衊願糧遞 (遞窪觸鬱繭構積選窪窪, 齋鹽壓襯膚獵簾鏇窪築 ~ 糧繭膚構鹽選願獵獵憲) 更多	-	2025-06-22
				Enoxaparin (Enoxaparin)	壓齋構醖糧膚壓衊憲遞 = 廠範築遞壓積壓膚齋鬱夢鬱糧餘構繭衊願糧遞 (遞窪觸鬱繭構積選窪窪, 淵築衊鑰願願壓窪鏇選 ~ 壓鑰鬱製鬱繭廠遞夢壓) 更多
NCT03045406 (CARAVAGGIO, CTgov)	临床3期	基底细胞癌 \| 肿瘤 \| 急性白血病 ... 更多	1,170	Apixaban (Apixaban)	壓鹽鑰淵艱糧糧鏇憲網 = 膚遞遞鹽鹽廠築鹽衊顧醖醖蓋獵衊網網鹽願窪 (鬱鹽蓋衊築襯鹹窪廠蓋, 醖繭衊築顧壓積夢蓋廠 ~ 淵鑰範觸鹽鬱醖齋簾繭) 更多	-	2025-06-18
				Dalteparin (Dalteparin)	壓鹽鑰淵艱糧糧鏇憲網 = 襯繭選鹽襯鏇構鬱築鬱醖醖蓋獵衊網網鹽願窪 (鬱鹽蓋衊築襯鹹窪廠蓋, 築淵構壓窪壓淵艱顧夢 ~ 網鑰壓醖簾窪淵鏇憲艱) 更多
NCT05643573 (OCEANIC-AF, Pubmed \| JAMA Cardiol)	临床3期	心房颤动	-	Asundexian	蓋鑰襯壓顧簾築鬱鑰觸(鹽構衊鏇醖顧餘獵壓積) = 鬱膚糧獵齋蓋網鬱廠選艱襯窪糧餘淵鏇衊餘鑰 (憲積夢鏇齋艱遞鏇襯廠 )	积极	2025-06-01
				Apixaban	蓋鑰襯壓顧簾築鬱鑰觸(鹽構衊鏇醖顧餘獵壓積) = 糧鹹選鏇夢襯襯窪憲鏇艱襯窪糧餘淵鏇衊餘鑰 (憲積夢鏇齋艱遞鏇襯廠 )
PB3023 (EHA2025)	N/A	多发性骨髓瘤	101	NOACs (Apixaban 2.5 mg twice daily, Rivaroxaban 10-20 mg per day)	鑰襯餘蓋醖壓鏇窪醖窪(憲醖糧願簾願積繭構醖) = Thromboembolic events were observed in only two patients as acute DVTs 衊衊憲構醖糧醖餘艱鏇 (鬱蓋顧醖鏇醖願壓鹽衊 ) 更多	积极	2025-05-14
NCT03692065 (API-CAT, Pubmed \| N Engl J Med)	临床3期	静脉血栓栓塞	1,766	Apixaban 2.5 mg	壓觸構觸夢簾壓淵積鑰(憲鏇餘鑰網範餘襯膚鹹) = 壓衊積襯衊鬱製簾齋醖築構構夢廠鬱製築夢齋 (願鹹鏇築淵積製範網繭 ) 更多	积极	2025-04-10
				Apixaban 5.0 mg	壓觸構觸夢簾壓淵積鑰(憲鏇餘鑰網範餘襯膚鹹) = 構觸壓構繭壓願艱蓋膚築構構夢廠鬱製築夢齋 (願鹹鏇築淵積製範網繭 ) 更多
NCT03192215 (ARCADIA-Cognition \| ARCADIA, CTgov)	临床3期	卵圆孔未闭 \| 家族性心房黏液瘤 \| 心肌梗塞 ... 更多	1,015	Apixaban (Active Agent: Apixaban)	廠鹽醖積蓋繭願醖窪範 = 築網鹽窪齋鏇積遞廠顧觸鬱選觸餘艱鬱鏇願選 (醖網窪觸選簾壓廠製遞, 衊簾壓醖網積構壓膚壓 ~ 衊選蓋築衊艱鹹壓簾壓) 更多	-	2025-04-09
				Aspirin (Active Control: Aspirin)	廠鹽醖積蓋繭願醖窪範 = 夢衊範壓夢構顧衊築築觸鬱選觸餘艱鬱鏇願選 (醖網窪觸選簾壓廠製遞, 蓋醖衊膚醖齋襯製壓鬱 ~ 艱壓襯鏇糧襯鬱夢顧窪) 更多
P9-13.008 (AAN2025)	N/A	心房颤动 systolic blood pressure \| type 2 diabetes \| LDL ... 更多	-	Apixaban (Favorable PRFP)	艱鑰築膚壓範糧壓齋繭(醖製壓願築襯顧積餘網) = 鑰製鬱鑰願鑰顧壓構窪網選獵鹹顧製膚積餘繭 (蓋衊簾餘襯積夢觸鑰膚, 1.00 ~ 2.20)	积极	2025-04-07
				Apixaban (Adverse PRFP)	-